J&J’s ketamine-derived nasal spray approved by FDA to treat depression
The Food and Drug Administration (FDA) approved Johnson & Johnson’s ketamine-derived nasal spray to help millions of U.S.
FDA approves Johnson & Johnson’s nasal spray for depression as stand-alone treatment
Spravato is now the first-ever stand-alone therapy for treatment-resistant depression, and is on its way to becoming a ...
Hosted on MSN8d
Johnson & Johnson ketamine-derived nasal spray gets FDA approval for depression, but JNJ stock dips on earnings
On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray, Spravato (esketamine), to treat ...
Yahoo Finance11d
FDA Approves Johnson & Johnson's Treatment As First Monotherapy For Treatment-Resistant Depression
On Tuesday, the FDA approved Johnson & Johnson’s (NYSE:JNJ) supplemental New Drug Application for Spravato (esketamine) CIII ...
FiercePharma10d
Johnson & Johnson's Spravato gains FDA nod to be used as a monotherapy
Already on its way to becoming a blockbuster drug, Johnson & Johnson’s Spravato has received another potential boost as the ...
ConsumerAffairs11d
FDA approves nasal spray drug to treat depression
Johnson & Johnson has announced that the U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal ...
Johnson & Johnson Announces a Major Acquisition. Can It Turn the Stock's Fortunes Around?
Johnson & Johnson (NYSE: JNJ) has a diverse healthcare business, and investors often look to it as a safe dividend stock to invest in for the long term. The company's growth is often in the single ...
mic10d
A Nasal Spray For Depression? FDA Gives Its Approval
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first ...
The FDA just approved this ketamine-derived nasal spray for depression treatment
The Food and Drug Administration (FDA) has approved Spravato, a nasal spray developed by Johnson & Johnson, as a standalone ...
Healio10d
FDA approves Spravato as monotherapy for adults with major depressive disorder
The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...
FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as stand-alone treatment
The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...